Related Experiment Video
Updated: Aug 16, 2026

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
Published on: July 2, 2013
Combinations of antibiotics against Pseudomonas aeruginosa
Abstract:
Pseudomonas aeruginosa continues to cause serious infections, especially bacteremias, in hospitalized and immunocompromised patients. During the past 10 years, bacteremia due to this organism has increased in frequency in many institutions, and mortality rates in patients with rapidly fatal disease remain as high as 85 percent despite antibiotic therapy. Available data do not allow firm conclusions regarding the in vivo predictive value of in vitro synergy testing for P. aeruginosa, but in vitro demonstration of synergy appears important in selecting therapy for patients with P. aeruginosa infections. Combinations of aminoglycosides (amikacin or tobramycin) with highly active antipseudomonal beta-lactam antibiotics are most likely to be associated with in vitro synergy. Experimental studies in animals models support the use of combination therapy for local and bacteremic infections. Similarly, the retrospective and prospective studies in humans suggest better survival with combinations of antimicrobials, usually including aminoglycosides and beta-lactams, in immunocompromised hosts. At present, the use of newer penicillins, piperacillin, azlocillin, or selected antipseudomonal cephalosporins, in combination with amikacin or tobramycin, appears to be the preferable antimicrobial therapy for serious P. aeruginosa infections.
Insights
Pseudomonas aeruginosa infections are increasing, with high mortality. Combination antibiotic therapy, particularly aminoglycosides with beta-lactams, shows promise for treating these serious bacterial infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Pseudomonas aeruginosa causes severe infections, especially bacteremias, in hospitalized and immunocompromised patients.
- The frequency of P. aeruginosa bacteremia has risen, with high mortality rates (up to 85%) despite treatment.
- In vitro synergy testing's predictive value for P. aeruginosa is not firmly established, but in vitro synergy is crucial for guiding therapy selection.
Purpose of the Study:
- To review the current evidence on combination antimicrobial therapy for serious Pseudomonas aeruginosa infections.
- To identify effective antibiotic combinations for P. aeruginosa based on in vitro synergy and clinical outcomes.
Main Methods:
- Review of available data on in vitro synergy testing for P. aeruginosa.
- Analysis of experimental animal studies supporting combination therapy.
- Evaluation of retrospective and prospective human studies on antimicrobial combinations.
Main Results:
- In vitro synergy is often demonstrated with combinations of aminoglycosides (amikacin, tobramycin) and antipseudomonal beta-lactams.
- Animal models support combination therapy for local and bacteremic P. aeruginosa infections.
- Human studies suggest improved survival with combination therapy, especially in immunocompromised hosts.
Conclusions:
- Combination therapy, particularly aminoglycosides with beta-lactams, is recommended for serious P. aeruginosa infections.
- Preferred regimens include newer penicillins (piperacillin, azlocillin) or cephalosporins combined with amikacin or tobramycin.
More Related Videos
Related Concept Videos
Antibiotic Selection
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management
Gene Regulation in Microbial Communities: Quorum Sensing
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance

